Unlocking an expansive target space to build a pipeline of novel,
TCR-based therapeutics.

Science Background

Our Science

At T-Cypher Bio we generate novel TCR-based therapeutics that have the potential to transform the treatment of immune-mediated disease. Our proprietary platforms provide unique insight into T cell based immunity in both health and disease. High throughput, high-resolution profiling of the immune synapse enables us to map the intracellular target space and profile T cell specificity. These platforms not only give us tools to build highly innovative drugs, but also build immune system data sets of unprecedented size. These data sets support cutting edge computational modelling of T cell repertoires which will revolutionize T cell immunology.

To build our oncology pipeline, we validate novel, shared, tumour-specific targets and identify panels of rare functionally-defined T cell clones. The unique TCRs we identify are the foundation of our broad pipeline of lifesaving therapeutics for underserved solid tumour patients.

Science Background

Latest News

Our Team and Investors

We are a passionate, committed, friendly and diverse group of experts. Our expertise spans immunology, AI & bioinformatics to T-cell biology. We are led by a team of scientific and business leaders with a track record of developing successful biotechnology companies to benefit patients. We share a deep sense of duty to work with passion and develop our leading technologies for the benefit of patients.

We are backed by leading, specialist, long-term investors who share our passion and who facilitate our path to delivering lifesaving therapeutics.

Science Background

Scientific Advisory Board

Professor Graham Ogg
SAB Chair
Professor Graham Ogg
Professor Sir Andrew McMichael
Sir Andrew McMichael
Professor Dame Fiona Powrie
Professor Fiona Powrie
Professor Tao Dong
Professor Tao Dong
Dr Nicola Ternette
Dr Nicola Ternette
Professor Cassian Yee
Dr Cassian Yee

Board Members

Thomas Lars Andresen
CEO
Thomas Lars Andresen
Claire Brown
Oxford Science Enterprises
Claire Brown
Phil Ferneau
Borealis, Observer
Phil Ferneau
Shyam Masrani
Medicxi
Shyam Masrani
Sohaib Mir 
Life Arc, Observer
Sohaib Mir

Leadership Team

Thomas Lars Andresen
CEO
Thomas Lars Andresen
Nathaniel Davies
Senior Director, Computational Biology
Nathaniel Davies
Mark Lees
VP Corporate Development
Mark Lees
Sarah Leonard
VP Preclinical Development
Sarah Leonard

Contact

The Sherard Building
Edmund Halley Road
Oxford
OX4 4DQ